Search

Displaying results 1041 - 1050 of 8517 in total
  1. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    Some clinical data has suggested that the clinically recommended dose of 250mg was too low. … It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.

  2. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named … [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.

  3. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.

  4. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]

  5. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  6. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  7. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … The latter indication was presented by Pernix Therapeutics.[L5974]

  8. Drug

    Betamethasone

    go.drugbank.com/drugs/DB00443
    ApprovedInvestigationalVet approved

    [A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444] … [A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.

  9. Drug

    Magnesium

    go.drugbank.com/drugs/DB14513
    ApprovedInvestigational

    Magnesium is classified as an alkaline earth metal and has 2 hydration shells. … [A19349] The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate.

    Mixtures: Luna Vitamin and Mineral Bar for Women
  10. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    [L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. … This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.